Back to top
more

Neurocrine Biosciences (NBIX)

(Real Time Quote from BATS)

$135.84 USD

135.84
483,089

-1.92 (-1.39%)

Updated Apr 26, 2024 03:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NBIX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Neurocrine Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,032 989 711 801 671
Receivables 439 350 186 157 127
Notes Receivable 0 0 0 0 0
Inventories 38 35 31 28 17
Other Current Assets 98 79 46 30 17
Total Current Assets 1,607 1,454 973 1,016 831
Net Property & Equipment 71 59 59 45 42
Investments & Advances 849 402 624 265 300
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 363 306 315 319 0
Intangibles 36 37 0 0 0
Deposits & Other Assets 50 25 4 6 59
Total Assets 3,251 2,369 2,073 1,735 1,306
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 170 169 0 0 0
Accounts Payable 449 348 226 169 141
Current Portion Long-Term Debt 0 0 0 0 409
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 36 21 20 18 15
Total Current Liabilities 655 538 246 187 565
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 335 318 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 106 30 12 10 17
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,019 661 699 609 669
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,382 2,122 2,011 1,850 1,768
Retained Earnings -157 -407 -636 -725 -1,133
Other Equity 7 -8 -2 2 1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 2,232 1,708 1,374 1,126 637
Total Liabilities & Shareholder's Equity 3,251 2,369 2,073 1,735 1,306
Total Common Equity 2,232 1,708 1,374 1,126 637
Shares Outstanding 98.20 96.10 94.80 93.90 92.00
Book Value Per Share 22.73 17.77 14.49 11.99 6.92

Fiscal Year End for Neurocrine Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 1,032 1,095 977 895
Receivables NA 439 418 388 392
Notes Receivable NA 0 0 0 0
Inventories NA 38 29 32 33
Other Current Assets NA 98 108 101 113
Total Current Assets NA 1,607 1,650 1,497 1,433
Net Property & Equipment NA 71 69 66 63
Investments & Advances NA 849 588 516 380
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 363 383 379 337
Intangibles NA 36 35 37 37
Deposits & Other Assets NA 50 43 36 25
Total Assets NA 3,251 2,848 2,613 2,360
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 170 170 170 0
Accounts Payable NA 449 503 392 356
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 36 19 21 18
Total Current Liabilities NA 655 692 583 374
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 170
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 69 89 41
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,019 846 760 675
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,382 2,309 2,242 2,171
Retained Earnings NA -157 -305 -388 -483
Other Equity NA 7 -2 -1 -3
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 2,232 2,002 1,853 1,685
Total Liabilities & Shareholder's Equity NA 3,251 2,848 2,613 2,360
Total Common Equity 0 2,232 2,002 1,853 1,685
Shares Outstanding 99.50 98.20 98.20 97.60 97.50
Book Value Per Share 0.00 22.73 20.39 18.99 17.28